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Effects of hypercapnia in sepsis: protocol
for a systematic review of clinical and
preclinical data
Thomas P. Clyde1, Michael Coletta1, Christopher Jones1, Hope Kilgannon1, Brian M. Fuller3, Stephen Trzeciak1,2
and Brian W. Roberts1*
Abstract
Background: Respiratory failure requiring mechanical ventilation is a common manifestation of end-organ damage
among patients with sepsis and has a high morbidity and mortality rate, as well as substantial associated treatment
costs. Considering the burden of this condition, there is great need to identify novel, pragmatic therapies to improve
outcomes in this population. Hypercapnia has shown benefits in several different ex vivo and in vivo models of lung
injury. However, it is currently unclear if hypercapnia can confer clinical benefit among patients with sepsis. The
objective of this systematic review is to collate the biomedical literature of preclinical and clinical studies testing the
effects of higher PaCO2 levels in the setting of sepsis.
Methods: We will perform a qualitative systematic review of preclinical and clinical studies evaluating the effects of
hypercapnia in sepsis. We will search CENTRAL, PubMed, CINAHL, and EMBASE using a comprehensive strategy. We
will screen the reference lists of the articles we select for inclusion to identify additional studies for potential inclusion.
Two independent reviewers will review all search results. Upon inclusion of articles, we will extract data using a
standardized form. We will use tables to describe the study type, population included, exposure and control
groups, outcome measures, and effects of exposure on outcome measures compared to controls.
Discussion: This systematic review aims to synthesize the world’s literature on the effects of hypercapnia in
the setting of sepsis. We expect this systematic review will find that majority of the studies will demonstrate
a potential benefit of higher PaCO2 levels in sepsis. The results of this systematic review will contribute to the
understanding of the effects of hypercapnia in the setting of sepsis and promote future research of PaCO2
management in mechanically ventilated patients with sepsis.
Systematic review registration: The systematic review is registered in the PROSPERO international prospective
register of systematic review (PROSPERO # CRD42018086703).
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Background
Sepsis places an enormous burden on healthcare systems
across the globe due to its high incidence, substantial
costs of treatment, and high mortality rate [1]. Patients
with septic shock often develop respiratory failure, with
as many as 80% requiring mechanical ventilation [2].
Sepsis patients requiring mechanical ventilation are at
high risk for ventilator-associated complications [3, 4]
and have a mortality rate approaching 50% [2, 5].
Considering the high incidence and mortality rate as-
sociated with mechanical ventilation among patients
with sepsis, there is a need to identify novel and prag-
matic approaches to improve outcomes in patients with
sepsis-associated respiratory failure.
The management of the partial pressure of arterial car-
bon dioxide (PaCO2) is a fundamental aspect of care in
all mechanically ventilated patients. The conventional
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paradigm dictates that the mechanical ventilator should
be adjusted to target a normal physiological PaCO2
range. However, data has shown that elevated PaCO2 in
the setting of a lung-protective ventilation strategy (i.e.,
permissive hypercapnia) is well tolerated and may be as-
sociated with improved survival among mechanically
ventilated patients with sepsis [6]. In addition to the ad-
vantages of low stretch ventilation, preclinical data sug-
gests hypercapnia may protect against systemic organ
injury through attenuation of inflammation and free rad-
ical generation [7, 8]. The ubiquitous need to manage
PaCO2, combined with data suggesting benefit associ-
ated with hypercapnia, suggests that PaCO2 could be
a target to improve outcomes in this vulnerable pa-
tient population.
The aim of this systematic review is to collate the bio-
medical literature of (1) preclinical studies testing the ef-
fects of higher PaCO2 levels in the setting of sepsis and
(2) clinical investigations testing the effects of hypercap-
nia on clinical outcomes in mechanically ventilated pa-
tients with sepsis. Our overarching hypothesis is that
the majority of the studies will demonstrate a poten-
tial benefit of higher PaCO2 levels in sepsis. If the
preponderance of data suggests hypercapnia attenu-
ates sepsis-induced injury, then this report will pro-
vide scientific rationale for implementing high-quality
interventional trials to test the effects of targeting ele-
vated PaCO2 levels in mechanically ventilated patients
with sepsis.
Methods/design
Protocol and registration
This systematic review protocol was prepared according
to the guidelines set forth in the Cochrane Handbook
for the Systematic Reviews of Interventions [9] and
Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) 2015 (Supplemen-
tal Material) [10]. This protocol’s PROSPERO registra-
tion number is CRD42018086703.
Search for and identification of studies
We will search CENTRAL, PubMed, CINAHL, and
EMBASE using the following search terms: “hypoventilation”
or “hypercapnia” or “hypercarbia” or “carbon dioxide” or
“CO2” AND “bacterial infection” or “pneumonia” or “sepsis”
or “septic shock” or “bacteremia.” We modeled our search
terms after search terms used in previously published
systematic reviews [11, 12]. We will also screen refer-
ence lists of the articles we select for inclusion to
identify additional studies for potential inclusion.
Eligibility criteria
We will include all study designs of the effects of hyper-
capnia in sepsis, severe sepsis, or septic shock. If a study
population does not meet the inclusion criteria but a
clearly defined subset of patients meets the inclusion cri-
teria, the study may be included; however, only data per-
taining to that subset of patients will be collected. The
inclusion criteria for preclinical studies are as follows:
(1) sepsis model (e.g., cecal ligation), (2) documented
measurement of PaCO2, and (3) comparison of outcome
measure between different PaCO2 levels. The inclusion
criteria for clinical studies are as follows: (1) patients di-
agnosed with sepsis (including severe sepsis and septic
shock; given we will be including paper regardless of
date of publication and the variation in sepsis definitions
over time, we will include any papers in which patients
are diagnosed with an infection and have some defin-
ition of systemic involvement), (2) patients receiving
invasive mechanical ventilation, (3) documented meas-
urement of PaCO2, and (4) comparison of outcomes be-
tween different PaCO2 levels. We will consider studies
eligible for review regardless of study design, language,
or publication type. We will exclude studies that are sec-
ondary reports of studies already included. We also will
exclude papers that are reviews, correspondence, or edi-
torials; however, we will screen the reference lists of re-
view articles to identify further studies for inclusion.
Study selection and data abstraction
Two independent reviewers will screen the titles and ab-
stracts of identified studies for potential eligibility. After
the relevance screen, the two reviewers will compare
their exclusion logs and use the kappa statistic to quan-
tify the inter-observer agreement. In cases of disagree-
ment, the full text will be reviewed for inclusion. All
studies deemed potentially relevant will be obtained and
the full manuscripts will be reviewed for inclusion.
Two reviewers will independently abstract data on all
patient populations, interventions, outcome measures,
adverse events, and results using a standardized data
collection form.
Assessment of study bias
We will follow the Cochrane Handbook’s recommen-
dations for assessing risk of bias in clinical and
non-clinical trials [9]. For clinical trials, we will use
the Cochrane Collaboration’s tool which evaluates risk
of bias in six domains: selection, performance, detec-
tion, attrition, reporting, and other biases [9]. For ob-
servational human studies, we will use the New
Castle-Ottawa Quality Assessment scale [9]. For ani-
mal models, we will use the Systematic Review Centre
for Laboratory Animal Experimentation’s (SYRCLE)
review of bias tool [13]. The overall strength of the
body of evidence will be assessed using the Grading
of Recommendations Assessment, Development and
Evaluation (GRADE) [14].
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Analysis
We will perform a primarily qualitative analysis of the
data in accordance with the recommended methodology
for qualitative reviews published in the Cochrane
Handbook [9]. We will first divide manuscripts into
two groups: (1) preclinical and (2) clinical.
For preclinical studies, we will table the following: (1)
animal model (e.g., mouse, pig); (2) study design (e.g., ran-
domized control trial, prospective cohort); (3) mechanism
for inducing sepsis (e.g., endotoxin); (4) PaCO2 categories;
(5) outcome measures, including primary and all second-
ary outcomes; (6) effects of hypercapnia on outcome mea-
sures; and (7) study quality (defined above).
For clinical studies, we will table the following: (1)
study design (e.g., cohort, randomized clinical trial); (2)
study population (i.e., study inclusion criteria, age, and
sepsis definition used); (3) PaCO2 categories; (4) out-
come measures, including primary and all secondary
outcomes; (5) effects of hypercapnia on outcome mea-
sures; and (6) study quality (defined above).
Protocol amendments
In the event of any changes to this protocol, each amend-
ment will be stated, a date will be provided for each
amendment, and the reasoning behind each amendment
will be made known.
Discussion
Sepsis-associated respiratory failure is a common cause
of morbidity and mortality, and its treatment requires an
enormous amount of medical resources [1, 15]. New,
cost-effective interventions are needed to address this
disease process. Hypercapnia has been proposed to
modulate gene expression, attenuate lung inflammation,
and mitigate ventilator-associated lung injury, thereby
potentially providing benefit to mechanically ventilated
patients with sepsis [16–20]. To our knowledge, there is
no systematic review of the world’s literature on the ef-
fects of hypercapnia in the setting of sepsis.
This systematic review aims to synthesize the world’s
literature on the effects of hypercapnia in the setting of
sepsis. We expect this systematic review will find that
the majority of the studies will demonstrate a potential
benefit of higher PaCO2 levels in sepsis. The results of
this systematic review will contribute to the understand-
ing of the effects of hypercapnia in the setting of sepsis
and promote future research of PaCO2 management in
mechanically ventilated patients with sepsis.
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